Final Program - Canadian Society of Hospital Pharmacists

More documents

Recommendations

Info

16 2. How can pharmacists integrate practical management strategies into the prevention and management of adverse effects associated with hepatitis C therapy? Jump In and Join Us! What’s the CSHP 2015 Temperature? CAROLYN BORNSTEIN, BSCPHM, ACPR, CGP, FCSHP, CSHP 2015 PROJECT COORDINATOR, NEWMARKET, ON CSHP 2015 is a vision of Pharmacy Practice Excellence. Its 6 goals aim to ensure that the use of medications is effective, evidence-based and safer, and to contribute meaningfully to public health. Thirty-six pharmacy practice-related objectives support the goals. This session will provide the most up-to-date information on the implementation of the CSHP 2015 objectives in hospital pharmacy departments in Canada, based on a CSHP 2015 online survey conducted in March-April 2012. What 2015 targets have been met or soon will be? What are the top 10 high priority objectives of the respondents’ pharmacy departments and how do they compare to their current or planned implementation? Which objectives are the lowest of lows for priority and should we be concerned? Are pharmacists in hospitals monitoring AND managing the medication use of patients with complex and high risk regimens? Are ambulatory patients provided the same services? Is evidence-based practice the norm for hospital pharmacists in Canada? Medication reconciliation implementation is definitely a priority on admission but why not on discharge? Are we reviewing the safety of the medication use annually? Are we evaluating our processes for compounding sterile products? What about technology? Why don’t we see more of it when we know it enhances medication safety? Should hospital pharmacies be involved in community health initiatives? Do we have emergency preparedness programs in place? Results will be compared to the 2009 survey. Some of the challenges to pursuing the CSHP 2015 objectives will be shared. What’s our biggest obstacle? What resources and/or assistance would respondents like CSHP to provide to support its members with CSHP 2015? Are the CSHP 2015 tool kits helpful and/or being used? Current resources and supports for CSHP members will be highlighted. Goals and Objectives 1. To provide highlights of the CSHP 2015 progress, or lack thereof, to date and share feedback from CSHP members on the challenges and barriers to achieving the CSHP 2015 targets 2. To highlight some of the many supports, resources and tools that CSHP has provided for its members, including future plans. Self-Assessment Questions 1. Name 3 of the top 10 high priority CSHP 2015 objectives based on the recent 2012 online survey. 2. Which objectives are considered very low priority according to the recent survey? 3. What are the CSHP 2015 virtual posters and where can they be found? Biologics in Arthritis: To the Rescue and Beyond? MARIE CRAIG, BSCPHM, THE ARTHRITIS PROGRAM, SOUTHLAKE REGIONAL HEALTH CENTRE, NEWMARKET, ON The purpose of this session is to discuss how the introduction of Biologics over a decade ago has changed the landscape of Arthritis care. This will be presented from the literature, clinical and patient perspective. A risk versus benefit treatment model for decision making utilized in patient teaching will be shared. The Crystal Osteoarthritis Rheumatoid and Enthesopathies (CORE) description of Rheumatic Diseases will be provided. The recent changes in the understanding of risk of Rheumatic diseases will be introduced. The treatment guidelines for Biologic use in Rheumatoid Arthritis versus their use in the Spondylarthropathies ie Psoriatic Arthritis and Ankylosing Spondylitis will be presented. Information from random controlled trials (RCT’s) versus the Biologic Registries indicating how Biologics are being used clinically will be discussed. The differences in pre-screening and the challenges that various biologics present re safety will be reviewed. What are the American College of Rheumatology (ACR) Guidelines re immunization of patients taking Biologics? What does the literature state re holding of Biologics pre-surgery? Recent insites re medical problems that also increase TNF and which may negatively impact the effectiveness of TNF Alpha Inhibitors will be introduced. A Canadian Rheumatology Association (CRA) approved website that provides biologic patient information will be shared. How can Pharmacists partner with hospitalized patients for improved safety and effectiveness? What medications are on the horizon that may compete with biologics and possibly shift the landscape again? Goals and Objectives 1. To evaluate the place in therapy of Biologics in Inflammatory Arthritis based on risk versus benefit and practice guidelines 2. To review the questions and concerns the studies and biologic registries present 3. To discuss how Pharmacists may partner with hospitalized Biologic patients for improved safety and effectiveness. Self-Assessment Questions 1. What atypical infections could the hospitalized patient be challenged by as a consequence of treatment with a biologic? 2. What vaccines are classified as “live” that are not recommended when a patient is taking a Biologic? Neuropathic Navigation: Finding Our Way to Improvements in Pain and Function JAMIE FALK, BSCPHM, PHARMD, WINNIPEG REGIONAL HEALTH AUTHORITY, WINNIPEG, MB
17 The purpose of this session is to provide an evidence-based look at the patient-centred management of neuropathic pain. The diagnosis and treatment of neuropathic pain continues to develop. Currently however, due to a lack of objectivity in assessment, numerous possible pathophysiologies, and the myriad of therapeutic options available, many without robust evidence and less than ideal adverse event profiles, the management pathways of neuropathic pain can be difficult to navigate, both for the clinician and the patient. In this session we’ll discuss principles that can be utilized as trail markers to help us guide our patients toward improved pain and functioning. This discussion will include the assessment of the patient’s unique neuropathic presentation, the identification and translation of risk and benefit likelihoods for pharmacological options that are understandable to both the clinician and the patient, and therapeutic considerations for more complicated individuals such as the elderly and those with multiple comorbidities. In addition, this session will explore the development of treatment and monitoring plans that involve close follow-up, a progressive approach to medication adjustment, and a focus on outcomes that are valuable to the patient. There are many unanswered questions in the treatment of neuropathic pain, but with the use of currently available evidence, well-established pharmacotherapeutic principles, and sound clinical judgment, the journey toward positive outcomes will be less fraught with roadblocks, misdirection, and confusion. Goals and Objectives 1. To provide a pharmacological basis for the numerous agents currently used in the treatment of neuropathic pain. 2. To provide an overview of the evidence supporting the various agents currently used to manage neuropathic pain, including onset, magnitude, and duration of effect on pain and functional improvement. 3. To discuss how utilization of the common adverse event profiles of these agents can help tailor medication regimens to the individual patient. 4. To highlight key aspects in the development of a well-defined, patient-centred monitoring plan for those with neuropathic pain. Self-Assessment Questions 1. What degree of benefit is possible with the first-line agents used for treatment of common neuropathic pain conditions? 2. What agents are reasonable second-line adjunct options for treatment of neuropathic pain and how does one decide on the appropriate one for the individual patient? Evolution of the Pharmacy Practice Model in the RQHR In 2008, a series of initiatives was begun with a focus on redeveloping the pharmacy practice model within the Regina Qu’Appelle Health Region. The rationale for this change included the concern that we had insufficient pharmacists to meet demands for service, the concern that our practice model was inconsistent in terms of the care provided from a patient perspective, our need to identify what we do for whom, in order to best train new members of our team, and the ongoing change in the evolution of pharmacy practice including prescriptive authority and pharmacist responsibility for outcomes. As a result we identified a number of goals that included: • Development of a patient-centric model of pharmacist care • Provision of clarity and consistency from a patient perspective in whom we prioritize for care and the activities we will perform • Development of a pharmacy practice model that ensures pharmacist job satisfaction by maximizing the patient care role of the pharmacist • Development of standards of practice that result in maximizing the role pharmacists have in direct patient care • Development of training tools consistent with standards of practice to ensure that new pharmacists are trained to provide consistent care to patients • Assurance that pharmacist care activities are consistent with prescriptive authority and pharmacist responsibility for outcomes • Development of a series of measures (Key Performance Indicators) to ensure that changes are improving the care we provide to patients • This session will discuss the process, findings and outcomes to date in the transition to a New Practice Model. Goals and Objectives The goal of the session is to provide attendees with: 1. An overview with the rationale and goals of the pharmacist practice model change within the RQHR 2. Insight into the process utilized in the practice model change in the RQHR 3. Results available to date in the practice model redesign in the RQHR Self-Assessment Questions 1. Why was it felt that a practice model design was necessary within the RQHR? 2. What were the greatest successes and challenges noted within the RQHR process? WILLIAM SEMCHUK, MSC, PHARMD, FCSHP, REGINA QU’APPELLE HEALTH REGION, REGINA, SK
Page 1: Let’s get our feet wet! On se mou
Page 4 and 5: 4 Dear Colleague: It is with great
Page 6 and 7: 6 Table of Contents Table des mati
Page 8 and 9: CSHP Research and Education Foundat
Page 10 and 11: 10 The Educational Services Committ
Page 12 and 13: 12 10:55-11:40 Concurrent Sessions
Page 14 and 15: 14 08:15-09:15 Plenary Session Séa
Page 18 and 19: 18 Warm, Cold, Wet, Dry: An Approac
Page 20 and 21: 20 children six years of age and ol
Page 22 and 23: 22 2. To describe how the concept o
Page 24 and 25: 24 1. What are the five elements of
Page 26 and 27: 26 Upcoming Events Événements à
Page 28 and 29: 28 provided for project management
Page 30 and 31: 30 Monday, August 13, 2012 Lundi 13
Page 32 and 33: 32 Emergency departments should sto
Page 34 and 35: 34 Failure to comply with requireme
Page 36 and 37: 36 Faculty CSHP would like to recog
Page 38 and 39: 38 Call for CSHP National Awards li
Page 40 and 41: 40 Exhibitor Hall Floor Plan Plan d
Page 42 and 43: Social Events at a glance SATURDAY
Page 44: Join Us! CSHP M EMBERSHIP HAS M ANY

Final Program - Canadian Society of Hospital Pharmacists

Create successful ePaper yourself

Delete template?

Save as template?